Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Randomized, Two-way Crossover, Single Dose, Pivotal Bioequivalence Study of a Fixed-dose Combination of Dolutegravir and Rilpivirine in Healthy Volunteers

NCT02741557 is registered in ClinicalTrials.gov with ViiV Healthcare as lead sponsor.

NCT NCT02741557
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02741557 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Randomized, Two-way Crossover, Single Dose, Pivotal Bioequivalence Study of a Fixed-dose Combination of Dolutegravir and Rilpivirine in Healthy Volunteers
Lead sponsor
ViiV Healthcare
Phase
Phase 1
Overall status
Completed
Start date
May 11, 2016
Completion date
October 24, 2016
Enrollment
118 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections, infection, human immunodeficiency virus